# Cochrane Library

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT02272868 (Continued)

# Inclusion criteria

- Availability of stool donor from family
- Patient's agreement to nasogastric tube placement

# Exclusion criteria

- PCDAI score < 15 or > 45
- Active or history of intra-abdominal abscess, perianal abscess, perianal fistula, intra-abdominal fistula, stricturing CD
- Other serious medical conditions (e.g. neurologic, liver, kidney, autoimmune, systemic disease)
- Allergy to any product used in study (e.g. rifaximin, omeprazole, MiraLAX)
- Pregnancy, lactation, child-bearing potential (unless abstinent or willing to use adequate birth control from screening to end of study)
- Intolerance to nasogastric tube placement (e.g. due to recent surgery or trauma to nares)
- Presence of condition or abnormality that may compromise patient safety or data quality, as deemed by investigator

# Interventions

# Experimental arm

- Pretransplant regimen (rifaxamin + omeprazole + MiraLAX) + donor FMT

# Control arm

- Pretransplant regimen (rifaxamin + omeprazole + MiraLAX) + normal saline

# Outcomes

# Primary outcome

- PCDAI at week 12

# Notes

Trial completed on 1 October 2016 with actual enrollment of 7 participants; no results available.

# Zhang 2019

# Methods

RCT

# Participants

# Inclusion criteria

Unavailable

# Exclusion criteria

Unavailable

# Interventions

# Experimental arm

- FMT

# Control arm

- Standard medical treatment: sulfasalazine tablets

# Outcomes

# Primary outcome

- Pre- and post-treatment inflammatory factors (CRP, interleukin-6, tumor necrosis factor-α)

# Secondary outcomes

- Sutherland Index score
- Intestinal flora score

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.